GeoVax Forms Five-Member Advisory Board for Gedeptin Solid Tumor Trials
GeoVax has formed a five-member oncology advisory board of solid tumor experts to guide Gedeptin development in melanoma, head and neck and pancreatic cancers. The board will advise on IND submission strategy, Phase I trial design and biomarker selection to accelerate the clinical program.
1. Advisory Board Established
GeoVax has appointed five oncology thought leaders to its new advisory board focused on solid tumor immunotherapy. Members bring expertise in melanoma, head and neck and pancreatic cancer to support strategic planning and program oversight.
2. Focus on Solid Tumor Development
Gedeptin, GeoVax’s conditionally replicating oncolytic adenovirus therapy, will benefit from the board’s guidance on preclinical data interpretation, patient selection criteria and combination strategies with existing treatments to maximize clinical impact.
3. Next Steps for Gedeptin Program
The advisory board will work with GeoVax to finalize the Investigational New Drug application, design a Phase I dose-escalation trial and develop biomarker panels for response monitoring, aiming to initiate first-in-human studies later this year.